Stone Run Capital’s Charles River Laboratories CRL Stock Holding History

Stone Run Capital’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-983	Closed	-$207K	–	59
2023 Q2	$207K	Buy	+983	New	+$196K	0.09%	57
2022 Q4	–	Sell	-1,133	Closed	-$223K	–	61
2022 Q3	$223K	Buy	+1,133	New	+$245K	0.12%	56
2022 Q2	–	Sell	-733	Closed	-$208K	–	61
2022 Q1	$208K	Buy	733 +6	+0.8%	+$1.85K	0.08%	64
2021 Q4	$274K	Sell	727 -330	-31%	-$128K	0.09%	57
2021 Q3	$436K	Buy	1,057 +288	+37%	+$120K	0.15%	56
2021 Q2	$284K	Buy	+769	New	+$257K	0.1%	60

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Stone Run Capital's CRL Position: Q3 2023 in Review

Stone Run Capital sold out of Charles River Laboratories (CRL) in Q3 2023, closing a stake of 983 shares — an estimated $207K sold.

Stone Run Capital first reported a position in CRL in Q2 2021 and held it in 6 quarters. The position peaked at $436K in Q3 2021. 621 funds tracked by Wall St. Rank hold CRL as of Q3 2023.

Stone Run Capital reported no remaining Charles River Laboratories position as of Q3 2023 after selling out during the quarter.
Stone Run Capital sold 983 Charles River Laboratories shares in Q3 2023, an estimated $207K.
Stone Run Capital first reported a position in Charles River Laboratories in Q2 2021 and held it in 6 quarters.
Stone Run Capital's Charles River Laboratories position peaked at $436K in Q3 2021.
621 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2023.

Based on Stone Run Capital's 13F filing for Q3 2023, filed 14 Nov 2023.